Mirvetuximab soravtansine: an oasis in the desert?

Authors :: Bonilla L
Kasherman L
Manso L
Madariaga A
Source :: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Apr 01; Vol. 34 (4), pp. 478-479. Date of Electronic Publication: 2024 Apr 01.
Publication Year :: 2024
Abstract: Competing Interests: Competing interests: AM has received honoraria from AstraZeneca, Clovis, GSK, MSD and PharmaMar. The remaining authors have no conflicts of interest to declare.

Subjects :: Humans
Female
Antibodies, Monoclonal, Humanized
Maytansine adverse effects
Maytansine analogs & derivatives
Immunoconjugates
Ovarian Neoplasms

Language :: English
ISSN :: 1525-1438
Volume :: 34
Issue :: 4
Database :: MEDLINE
Journal :: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publication Type :: Editorial & Opinion
Accession number :: 38388176
Full Text :: https://doi.org/10.1136/ijgc-2024-005400